Richard F. Chambers
Directeur Général chez Acxit Lifesciences GmbH
Profil
Richard F.
Chambers is currently the Managing Director at Acxit Lifesciences GmbH and a Member-Supervisory Board at ProBioGen AG.
He previously served as a Director at anwerina AG, a Member-Supervisory Board at curasan AG from 2007 to 2017, and the Chief Financial Officer at Heidelberg Pharma AG.
He obtained his undergraduate degree from Technische Universität Darmstadt.
Postes actifs de Richard F. Chambers
| Sociétés | Poste | Début |
|---|---|---|
ProBioGen AG
 ProBioGen AG Miscellaneous Commercial ServicesCommercial Services ProBioGen AG operates as a contract development and manufacturing organization. It specializes in cell line engineering, process development, and GMP manufacturing of biopharmaceuticals. The firm offers services such as cell line development, process development, manufacturing programs, physio-chemical analyses, and cell-based assays. The company was founded by Uwe Marx on June 13, 1994 and is headquartered in Berlin, Germany. | Directeur/Membre du Conseil | - |
Acxit Lifesciences GmbH
 Acxit Lifesciences GmbH Investment ManagersFinance Acxit Lifesciences GmbH provides financial and strategic advisory services. The private company is based in Frankfurt, Germany. Richard F. Chambers has been the CEO of the German company since 2004. | Directeur Général | 01/01/2004 |
Anciens postes connus de Richard F. Chambers
| Sociétés | Poste | Fin |
|---|---|---|
| CURASAN AG | Directeur/Membre du Conseil | 29/06/2017 |
| HEIDELBERG PHARMA AG | Directeur Financier/CFO | - |
anwerina AG
 anwerina AG Miscellaneous Commercial ServicesCommercial Services Anwerina AG is a pharmaceutical company based in Germany that specializes in the development of quality drugs and medical technology for the treatment of bone diseases. The Swiss company is experts in the field of osteoporosis and have a patient-centered strategy for the development of unique and cost-effective drugs. The private company offers ASCENDRA® / ASCENDRA® DUO / ASCENDRA® TRIO, which is an injection solution used for the therapy of osteoporosis in postmenopausal women with an increased risk of fractures. The company also focuses on the development of generic drugs for patients with bone metastases in the field of oncology. | Directeur/Membre du Conseil | - |
Formation de Richard F. Chambers
| Technische Universität Darmstadt | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| HEIDELBERG PHARMA AG | Health Technology |
| Entreprise privées | 4 |
|---|---|
ProBioGen AG
ProBioGen AG Miscellaneous Commercial ServicesCommercial Services ProBioGen AG operates as a contract development and manufacturing organization. It specializes in cell line engineering, process development, and GMP manufacturing of biopharmaceuticals. The firm offers services such as cell line development, process development, manufacturing programs, physio-chemical analyses, and cell-based assays. The company was founded by Uwe Marx on June 13, 1994 and is headquartered in Berlin, Germany. | Commercial Services |
curasan AG
 curasan AG Pharmaceuticals: MajorHealth Technology curasan AG engages in the developing, manufacturing and marketing of regenerative medicine. Its products cover the fields of bone and tissue regeneration, tissue engineering, and wound healing for dental, spinal and orthopedic applications. The company was founded by Hans Dieter Rössler in 1988 and is headquartered in Frankfurt, Germany. | Health Technology |
anwerina AG
anwerina AG Miscellaneous Commercial ServicesCommercial Services Anwerina AG is a pharmaceutical company based in Germany that specializes in the development of quality drugs and medical technology for the treatment of bone diseases. The Swiss company is experts in the field of osteoporosis and have a patient-centered strategy for the development of unique and cost-effective drugs. The private company offers ASCENDRA® / ASCENDRA® DUO / ASCENDRA® TRIO, which is an injection solution used for the therapy of osteoporosis in postmenopausal women with an increased risk of fractures. The company also focuses on the development of generic drugs for patients with bone metastases in the field of oncology. | Commercial Services |
Acxit Lifesciences GmbH
Acxit Lifesciences GmbH Investment ManagersFinance Acxit Lifesciences GmbH provides financial and strategic advisory services. The private company is based in Frankfurt, Germany. Richard F. Chambers has been the CEO of the German company since 2004. | Finance |
